BIOTECHNOLOGY

articles with this tag

$2.6M Capped eSense-Lab Signs US$600k Revenue Deal

$2.6M Capped eSense-Lab Signs US$600k Revenue Deal

Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.

OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe

OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe

OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).

Thanks for subscribing!

X